Jason R. Westin

29.1k total citations · 2 hit papers
224 papers, 6.0k citations indexed

About

Jason R. Westin is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Jason R. Westin has authored 224 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Pathology and Forensic Medicine, 146 papers in Oncology and 63 papers in Genetics. Recurrent topics in Jason R. Westin's work include Lymphoma Diagnosis and Treatment (156 papers), CAR-T cell therapy research (94 papers) and Chronic Lymphocytic Leukemia Research (61 papers). Jason R. Westin is often cited by papers focused on Lymphoma Diagnosis and Treatment (156 papers), CAR-T cell therapy research (94 papers) and Chronic Lymphocytic Leukemia Research (61 papers). Jason R. Westin collaborates with scholars based in United States, Australia and Germany. Jason R. Westin's co-authors include Sattva S. Neelapu, Elizabeth J. Shpall, Katayoun Rezvani, Frederick L. Locke, Partow Kebriaei, Sherry Adkins, Cristina Gutiérrez, Naval Daver, Krishna V. Komanduri and William G. Wierda and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Jason R. Westin

200 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations Sattva S. Neelapu, Partow Kebriaei et al. profile →
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

2017 1.0k citations Sattva S. Neelapu, Jason R. Westin et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason R. Westin United States	30	4.5k	2.4k	1.1k	1.1k	962	224	6.0k
Sunita D. Nasta United States	29	3.3k 0.7×	1.7k 0.7×	979 0.9×	876 0.8×	695 0.7×	179	4.7k
Craig S. Sauter United States	29	3.4k 0.8×	1.2k 0.5×	973 0.8×	777 0.7×	598 0.6×	189	4.7k
Frederick L. Locke United States	34	5.2k 1.1×	977 0.4×	1.4k 1.2×	1.4k 1.3×	308 0.3×	307	6.0k
Leslie Popplewell United States	34	2.8k 0.6×	2.0k 0.8×	1.1k 1.0×	1.1k 1.0×	751 0.8×	202	5.0k
Anthony R. Mato United States	24	1.9k 0.4×	1.1k 0.4×	619 0.5×	632 0.6×	746 0.8×	85	2.8k
Andres Forero‐Torres United States	39	5.1k 1.1×	3.5k 1.4×	1.6k 1.4×	1.2k 1.1×	1.4k 1.4×	162	7.6k
Roch Houot France	38	2.7k 0.6×	1.5k 0.6×	1.9k 1.6×	645 0.6×	631 0.7×	181	4.3k
Andreas Viardot Germany	28	3.0k 0.7×	2.0k 0.8×	1.1k 0.9×	599 0.5×	806 0.8×	131	4.6k
Alex F. Herrera United States	28	2.5k 0.6×	2.1k 0.9×	642 0.6×	392 0.3×	587 0.6×	239	3.5k
Saad S. Kenderian United States	25	2.1k 0.5×	527 0.2×	790 0.7×	737 0.7×	559 0.6×	149	2.9k

Countries citing papers authored by Jason R. Westin

Since Specialization

Citations

This map shows the geographic impact of Jason R. Westin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason R. Westin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason R. Westin more than expected).

Fields of papers citing papers by Jason R. Westin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason R. Westin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason R. Westin. The network helps show where Jason R. Westin may publish in the future.

Co-authorship network of co-authors of Jason R. Westin

This figure shows the co-authorship network connecting the top 25 collaborators of Jason R. Westin. A scholar is included among the top collaborators of Jason R. Westin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason R. Westin. Jason R. Westin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jacobson, Caron A., Jason R. Westin, David B. Miklos, et al.. (2025). Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial. Clinical Cancer Research. 32(5). 894–904.

Li, Meng, Rahul K. Shah, Ruitao Lin, et al.. (2025). Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019. Blood Advances. 10(5). 1713–1721.

Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2025). Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Journal of Clinical Oncology. 43(34). 3652–3661.

Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2024). Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Advances. 8(11). 2982–2990. 4 indexed citations

Goldstein, Jordan, Mark Roschewski, Won-Seog Kim, et al.. (2024). Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL. Blood. 144(Supplement 1). 651–651.

Westin, Jason R., Loretta J. Nastoupil, Ranjit Nair, et al.. (2024). Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7044–7044. 4 indexed citations

Hoffmann, Marc, Theodoros P. Vassilakopoulos, Javier Muñoz, et al.. (2024). Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma. Blood. 144(Supplement 1). 1742.2–1742.2. 1 indexed citations

Fang, Penny, Sonal S. Noticewala, Susan Wu, et al.. (2024). Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?. Advances in Radiation Oncology. 9(12). 101650–101650.

Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2023). Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study. Transplantation and Cellular Therapy. 29(2). S371–S372. 1 indexed citations

10.

Westin, Jason R., Caron A. Jacobson, Julio C. Chávez, et al.. (2023). PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA. HemaSphere. 7(S3). e3278692–e3278692. 1 indexed citations

11.

Lue, Jennifer Kimberly, Don A. Stevens, Emmeline Ayers, et al.. (2023). PHASE 1 TRIAL OF KT‐413, A DEGRADER OF IRAK4 AND IMID SUBSTRATES, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN’S LYMPHOMAS. Hematological Oncology. 41(S2). 808–809.

12.

Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2023). MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS. Hematological Oncology. 41(S2). 177–179. 5 indexed citations

13.

Jain, Preetesh, Hun Ju Lee, Jason R. Westin, et al.. (2023). Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. Blood. 142(Supplement 1). 1688–1688. 1 indexed citations

14.

Nastoupil, Loretta J., Jason R. Westin, Nathan Fowler, et al.. (2022). Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Advances. 6(4). 1143–1151. 29 indexed citations

15.

Westin, Jason R. & Laurie H. Sehn. (2022). CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?. Blood. 139(18). 2737–2746. 93 indexed citations

16.

Phillips, Tycel, Adam J. Olszewski, Javier Muñoz, et al.. (2020). Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma. Blood. 136(Supplement 1). 37–38. 37 indexed citations

17.

Lewis, Katharine L., Preetesh Jain, Yun Qing, et al.. (2020). Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study. British Journal of Haematology. 191(5). 806–815. 7 indexed citations

18.

Pham, Lan V., Shengjian Huang, Hui Zhang, et al.. (2018). Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clinical Cancer Research. 24(16). 3967–3980. 63 indexed citations

19.

Chihara, Dai, Nathan Fowler, Yasuhiro Oki, et al.. (2017). Difference in Survival Outcome of Primary Central Nervous System Lymphoma By Histologic Types. Blood. 130. 4137–4137. 1 indexed citations

20.

Strati, Paolo, Yasuhiro Oki, Luis Fayad, et al.. (2014). A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. Blood. 130(21). 4074–4074. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact